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Abstract 
 
Renal cell carcinoma (RCC) is the most common type of kidney cancer in adults. Nephron 
sparing resection (partial nephrectomy) has been the “gold standard” for the treatment of 
resectable disease. With the widespread use of cross sectional imaging techniques, more 
cases of renal cell cancers are detected at an early stage, i.e. stage 1A or 1B.  This has 
provided an impetus for expanding the nephron sparing options and especially, 
percutaneous ablative techniques.  Percutaneous ablation for RCC is now performed as a 
standard therapeutic nephron-sparing option in patients who are poor candidates for 
resection or when there is a need to preserve renal function due to comorbid conditions, 
multiple renal cell carcinomas, and/or heritable renal cancer syndromes. During the last 
few years, percutaneous cryoablation has been gaining acceptance as a curative treatment 
option for small renal cancers. Clinical studies to date indicate that cryoablation is a safe 
and effective therapeutic method with acceptable short and long term outcomes and with a 
low risk, in the appropriate setting.  In addition it seems to offer some advantages over 
radio frequency ablation (RFA) and other thermal ablation techniques for renal masses. 
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Introduction 
 
Renal cell carcinoma (RCC) is the most 
common type of kidney cancer in adults 
and the third most common malignancy of 
the urinary tract. With the advance and 
increasing use of cross sectional imaging 
techniques more cases of RCC are detected 
at an early stage and when they are 
clinically occult (1).  Surgical resection has 
been considered the standard of care for 
patients with localized RCC with partial 
nephrectomy traditionally being the 
intervention of choice.  Despite this, most 
patients undergo radical nephrectomy, as 
the availability of physicians able to 
perform partial nephrectomy has not kept 
up with demand.  The increased incidence 
of small renal masses resulted in the 
development of nephron sparing surgical 
techniques aiming at preserving renal 
function. Partial nephrectomy when 
feasible, either open or laparoscopic, is 
considered now the gold standard 
treatment for this subgroup of patients (2). 
Many patients however are poor surgical 
candidates, due to old age, the presence of 
comorbidities, multiple tumors, or 
compromised renal function. All of the 
above facilitated the introduction of less 
invasive ablative techniques as an 
alternative to extirpative surgical 
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Figure 1. The physics of cryoablation. Ex-vivo appearance of the formed ice-ball on a Cryoprobe (a).  
In human tissue the margin of the ice-ball represents the zero degree (Celsius) isotherm, which is not 
lethal.  As the argon gas drops in pressure it cools substantially and absorbs energy (Q), which is 
carried away by the warmed gas and released in the room (inert gas).  D is the diameter of the visible 
ice ball (b).  The pressurized argon is released inside the probe (no gas is released in the patient).  As 
the pressure drops it cools forming the ice-ball.  The lethal ablation zone is 3-5 mm inside the visible 
ice-ball (c). 
 
 
management for selected patients. Several 
studies demonstrated that ablative 
techniques can achieve effective local 
tumor control and are associated with less 
renal parenchymal loss and morbidity than 
partial nephrectomy (3). The recent 
American Urological Association (AUA) 
guidelines for the management of clinical 
stage T1 renal mass recognize both 
radiofrequency ablation (RFA) and 
cryoablation as viable treatment options for 
selected patients (4). Ablative methods were 
first widely used for liver lesions. Renal 
ablation has also been used during open or 
laparoscopic surgery since 1995 (5).  
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Figure 2. Schematic representation of the relevant isotherms during renal cryoablation. The 
temperature precipitously increases with distance from the probe. The temperature plot is shown in 
the upper portion of the figure. The 0o C isotherm is visible and represents the margin of the ‘‘ice-
ball,’’ which is not lethal. Lethal temperature for renal tissue is -20-25o C. This isotherm is not visible 
and resides at a certain distance within the visible ‘‘ice-ball.’’ For effective cryoablation, the nonvisible 
lethal isotherm must cover the entire target lesion (arrowhead). Note the ‘‘ghost’’ (dark line spearing 
the target lesion) of the removed cryoprobe as the tissue is still frozen and not collapsed. 
 
 
Current Literature on Percutaneous 
Cryoablation 
 
Recently percutaneous ablation techniques 
have been gaining acceptance and 
popularity as nephron sparing treatment 
for low stage RCC, based upon favorable 
outcomes in initial studies, low incidence of 
serious complications, less immediate 
morbidity and mortality compared to 
surgery, lower cost and faster mobilization 
(6).  Several studies demonstrated that 
short and intermediate outcome data 
following percutaneous thermal energy 
ablation were comparable to surgery, with 
clinical success of 90% overall and even 
greater (more than 95%) for tumors smaller 
than 3cm (7, 8). Psutka et al. reported that 
RFA can provide a durable long term 
oncologic outcome in patients with T1 renal 
cancer. They retrospectively reviewed the 
long-term oncologic outcome for 185 
patients with sporadic T1 RCC and median 
follow-up of 6.43 yr. The authors reported a 
5-yr recurrence free survival (RFS) of 
95.2%, 5-yr disease free survival (DFS) of 
88.6%, and 5-yr cancer specific survival 
(CSS) of 99.4%. (9). Oleweny et al. recently 
reported comparable 5-yr survival rates for 
RFA and partial nephrectomy in matched 
contemporaneous cohorts (97.2% vs 100%; 
p= 0.31) (10).  
 
During the last few years percutaneous 
cryoablation has been gaining over thermal 
ablative techniques as a curative option for 
small renal cancers. Renal cryoablation 
was established as a treatment option for 
renal cancers even before percutaneous 
RFA as part of open or laparoscopic 
surgery. With the introduction of thin 
cryoprobes percutaneous approach was 
made feasible.  
 
Cryoablation seems to offer some 
advantages over RFA and other thermal 
ablation techniques for renal masses. 
Imaging guidance (CT) allows direct 
Maria et al.                                                                                                               Cryoablation of renal cell carcinoma                                                                                       
Journal of Kidney Cancer and VHL 2015; 2(3):105-113.             http://jkcvhl.com 108 
 
 
Figure 3. Determination of the lethal cryoablation zone during an animal experiment.  The ice-ball is 
indicated by the dashed line on the CT (A), the blue line on the histopathological slide (B) and the 
arrow on the gross specimen (C).  The lethal ablation zone is smaller than the ice-ball and indicated 
by the green line on the histopathological slide (B).  On the gross specimen (c), the lethal zone appears 
as a red circle inside the ice-ball.  In this experiment, the distance between the visible ice- ball and 
the lethal ablation zone was determined to be about 3 mm (23). 
 
 
visualization of the ice ball, permitting 
more precise monitoring of the ablation 
zone (6).  It also allows the simultaneous 
use and synergy of more than one probe, 
thus sculpting the ice-ball. Additionally 
investigators showed that cryoablation has 
a reduced risk of thermal injury to the 
collecting system for centrally located 
tumors (11). This was also recently 
confirmed by Rosenberg et al. in a series of 
41 patients with ice balls overlapping the 
renal sinus by 6 mm or more (12).  A meta-
analysis of reported cryoablation vs RFA for 
small renal masses was published by 
Kunkle and Uzzo in October 2007 (5).  They 
analyzed the results from forty-seven 
studies including 1375 renal masses. The 
meta-analysis demonstrated that repeat 
ablation was performed more often after 
RFA (8.5% vs. 1.5%) and the rates of local 
tumor progression (which includes initial 
subtotal treatment and late local 
recurrence) were significantly higher for 
RFA compared with cryoablation, 12.9% vs. 
5.2%, respectively.  Atwell et al. in 2012 
studied 445 tumors measuring 3.0 cm or 
smaller treated with thermal ablation (256 
tumors were treated with RFA and 189 
tumors were treated with cryoablation). 
They suggested that the two methods are 
equally effective, having similar major 
complications and technical success, 
although cryoablation may be more 
efficacious for central tumors near the 
renal hilum (13). 
 
Different studies compared the efficacy of 
percutaneous and laparoscopic approaches 
for cryoablation. An analysis of the 
literature on renal cryoablation from 1966 
to 2010 in which 28 laparoscopic studies 
were compared with 14 percutaneous 
studies (in total, 1447 tumors) did not 
show a significant difference in terms of 
rate of residual tumors (p = 0.25) or rate of 
recurrent tumor (p = 0.44). The patient 
groups were comparable in terms of age, 
tumor size, and duration of follow-up (14). 
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Figure 4. Coronal reformatted, CT of the left kidney (A) showing a central biopsy proven renal cell 
carcinoma (arrows).  The intra-procedural coronal image shows the 5 cryyoprobes resulting in a lower 
density ice-ball (B, arrows).  Three month follow up CT (C) shows complete lack of enhancement of the 
necrotic tumor (arrows). 
 
 
There are several retrospective studies 
supporting the short and midterm outcome 
and efficacy of percutaneous renal 
cryoablation. Atwell et al. retrospectively 
reviewed 93 tumors treated with 
percutaneous cryoablation, with a mean 
size of 34 mm. They reported technical 
success rate of 96% with local tumor 
control in 95% of tumors and 1 case of 
local tumor progression seen on follow-up 
(15).  In previous studies with smaller 
series of patients other authors reported 
local control rates ranging from 83% - 95% 
based on short term follow up (16, 17, 18, 
19).  In a prospective study, Buy et al. 
reviewed 120 tumors with a mean size of 
26 mm. They reported a technical success 
rate of 94% with two tumors requiring 
second session of cryoablation (either due 
to recurrence or residual tumor) with 
disease free survival rate at 1 year of 96.7% 
(20). 
 
More recently Georgiades et al. published 
the results of a long-term, prospective 
study reporting efficacy and safety of 
percutaneous cryoablation for 265 stage 
1A/B renal cancers treated over a period of 
5 years.  The 5-year cancer specific survival 
was 100% and the 5-year recurrence free 
survival was 97%. He reported also an 
overall significant complication rate of 6%, 
lower than that of other surgical options, 
with the most frequent being transfusion-
requiring hemorrhage at 1.6% (21).  The 
patients in this study were not limited to 
those with contraindication to surgery.  
These results are comparable to the gold-
standard (partial nephrectomy) in terms of 
efficacy, and better in terms of safety. 
 
Physics of Cryoablation 
 
Pressurized argon (or other gases that obey 
the Joules-Thomson law) flows through the 
double-tubed cryoprobe and as it expands 
(still inside the probe), cools (Figure 1).  
Temperature below −20°C has been shown 
to be sufficient for complete destruction of 
normal renal parenchyma.  Though not 
substantiated, many authors believe that 
neoplastic cells are more cryoresistant and 
may require temperatures as low as −40°C 
to ensure cell death.  Preclinical models 
demonstrated that lethal temperatures (the 
ablation zone) can only be achieved within 
a core volume of tissue at a minimum 
distance of 3 mm from the edge of the 
visible ice ball (22, 23) (Figures 1, 2 and 
3). Multiple cryoprobes can be used 
simultaneously. They act synergistically 
resulting in the formation of even bigger ice 
ball that can encompass larger tumors. 
Probes should be positioned 1 cm from the 
tumor margin and 2 cm from each other 
(Figure 4).  
 
Cell death during cryoablation is 
multifactorial. The freezing-thawing cycle 
that results in both intra and extracellular 
ice crystal formation, leading to cellular 
membrane disruption and cell death.  
Additionally, vessel thrombosis results in 
ischemic death and finally, low 
temperatures initiate the process of 
apoptosis (24). 
 
Maria et al.                                                                                                               Cryoablation of renal cell carcinoma                                                                                       
Journal of Kidney Cancer and VHL 2015; 2(3):105-113.             http://jkcvhl.com 110 
 
 
Figure 5. Contrast enhanced, CT scan before cryoablation with axial (A) and coronal (B) reformations 
show T1a stage exophytic tumor (white arrows).  Contrast enhanced, CT scan at 9 months post-
cryoablation with axial (C) and coronal (D) reformations show no mass enhancement, confirming 
complete necrosis of the tumor.  The inflammatory rim (white arrowheads) is noted representing the 
edge of the ablation zone and not residual disease. 
 
 
Patient selection 
 
Before proceeding to cryoablation all 
patients should undergo a multiphasic CT 
or MRI scan. Pre-procedural imaging 
evaluation is necessary to ensure the 
patient is a candidate for curative 
intervention.  In general, patients with 
stage 1A or B are candidates for curative 
cryoablation.  Cross-sectional imaging also 
allows assessment of the size and location 
of the mass so that the interventional 
radiologist can plan the procedure, 
including number of probes, trajectory and 
possible risk factors. Vital structures in 
close proximity to the tumor such as the 
bowel, can be displaced using water, 
carbon dioxide or balloons. Placement of a 
temporary ureteral catheter before the 
procedure with or without continuous 
infusion with warm saline can minimize the 
risk of injury to the ureter. The procedure 
can be performed under conscious 
sedation. Biopsy should be performed 
either before or at the time of ablation to 
provide information for further 
management of the patient.  
Follow up 
 
Although there is no widely accepted post-
ablation imaging surveillance protocol to 
date, imaging at 3-, 6-, 9-, and 12-month 
post-ablation with contrast-enhanced CT or 
MRI and at 12-month intervals thereafter, 
is more than adequate (25).  The best 
indicator of complete ablation is lack of 
enhancement of a previously enhancing 
mass (Figure 5).  Persistent, ring-type 
enhancement at the edge of the ablation 
zone can be seen in most cases and it does 
not represent residual tumor, rather 
inflammatory response at the ice-ball 
margin (26).  Nodular or tumor 
enhancement, on the other hand should 
raise concern for incomplete treatment or 
disease recurrence. 
 
Renal Healing and Function 
 
Since the ablated tissue is not removed, 
healing is effected by absorption of the 
dead tissue over time.  Over a period of 
months the dead tissue involutes, shrinks 
and is eventually replaced by scar tissue.  
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Viability of the tumor on follow up imaging 
relies in contrast enhancement.  If there is 
complete lack of contrast enhancement of a 
previously enhancing mass, this is a sign of 
complete necrosis.  Many studies have 
shown that renal function is not affected by 
percutaneous ablation.  Both creatinine 
and renal clearance remain stable and the 
need for dialysis is extremely rare, limited 
to patients with advanced renal disease 
and nearly always temporary (17, 21, 27). 
 
Results and Conclusion 
 
The most rigorous study on the safety and 
efficacy of image-guided, percutaneous 
cryoablation for RCC was published by 
Georgiades et al. (21).  The authors treated 
134 patients with biopsy proven RCC with 
cryoablation under CT guidance.  Patients 
included those with stage 1A and B.  The 
1-, 2-, 3-, 4-, and 5-year efficacy of 
percutaneous cryoablation for RCC was 
99.2, 99.2, 98.9, 98.5, and 97.0%, 
respectively. Median tumor size was 2.8 ± 
1.4 cm. All-cause mortality during the 
study period was 3 (none from RCC), 
yielding an overall 5-year survival of 97.8%. 
The cancer-specific 5-year survival was 
100%. No patient developed metastatic 
disease during the follow-up period. The 
overall significant Common Terminology 
Agreement for Adverse Events (CTCAE) 
version 4.0 complication rate was 6%, with 
the most frequent being transfusion-
requiring hemorrhage, at 1.6%. There was 
one 30-day-mortality unrelated to the 
procedure.  
  
Percutaneous ablation of renal tumors 
under imaging guidance is now a widely 
accepted nephron sparing curative 
treatment option for patients who are poor 
surgical candidates or patients who wish to 
avoid surgery. These recommendations are 
supported by prospective, long-term 
studies (5-year) (21).  Treatment failure and 
local recurrence are uncommon, 
comparable to that of partial-nephrectomy 
and do not preclude repeat treatment. In 
addition, cryoablation appears to be safer 
than any surgical option.  Based on these 
data, patients with tumors that are stage 
1A or B amenable to percutaneous 
cryoablation, should be offered the option 
of percutaneous, image guided cryoablation 
(or thermal ablation). 
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